Ondine Biomedical (AIM:OBI) announced it has agreed a commercial partnership with Hospital Ángeles Health System to pilot its Steriwave nasal photodisinfection treatment at two flagship hospitals in Mexico.
The AIM-listed company develops light-activated antimicrobial therapies aimed at preventing hospital-acquired infections.
Hospital Ángeles is buying Steriwave treatments for use at Hospital Ángeles Acoxpa in Mexico City and Hospital Ángeles Valle Oriente in Monterrey, with a broader network rollout to be evaluated once the pilots are complete.
The deployment follows Ondine's Phase 3 pivotal trial, a 5,188-patient study across Canadian and US hospitals, which showed Steriwave's five-minute light-activated treatment cut post-surgical infection rates by 40% versus standard care alone.
Hospital Ángeles operates 27 hospital complexes across Mexico, performs roughly 150,000 surgeries annually, and runs a growing fleet of surgical robots including da Vinci Xi and Mako SmartRobotics systems.
Acoxpa is positioned as a high-volume robotic surgery hub, while Valle Oriente serves a domestic and international patient base for complex orthopedic and cardiovascular procedures.
"By integrating Steriwave's rapid, antibiotic-free infection control into Hospital Ángeles' surgical pathways, we are working towards setting a new standard for patient safety that directly addresses the top priority of international patients," said Carolyn Cross, chief executive of Ondine Biomedical.
Mexico attracts approximately 1.4 million medical tourists annually, according to Mexico Business News, positioning Hospital Ángeles at the centre of the country's surgical tourism market.
The pilots are already underway at both sites.
News Intelligence what this means for the company
Ondine has secured its first commercial deployment of Steriwave in Latin America, piloting the nasal photodisinfection treatment at two flagship hospitals within Mexico's largest private hospital network—Hospital Ángeles, which operates 27 complexes and performs ~150,000 surgeries annually. The deal follows Phase 3 results showing a 40% reduction in post-surgical infection rates, and positions Ondine to test market adoption in a high-volume surgical environment serving 1.4 million medical tourists annually, with potential for broader network rollout once pilots conclude.
- Pilots already underway at both sites signal rapid commercialisation momentum beyond North America and Europe, where Ondine has regulatory clearance; Mexico deployment tests the company's ability to penetrate international surgical tourism markets where infection prevention is a competitive differentiator.
- Hospital Ángeles' robotic surgery infrastructure (da Vinci Xi, Mako SmartRobotics) and focus on complex orthopedic and cardiovascular procedures align with Steriwave's surgical site infection reduction profile, potentially creating a repeatable playbook for adoption at other high-acuity robotic surgery centres.
Success at Hospital Ángeles could accelerate the broader network rollout and strengthen Ondine's negotiating position with other large hospital operators ahead of anticipated US regulatory submissions.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
